Sanofi-Synthelabo acquires rights
Atrix has granted Sanofi0-Synthelabo the exclusive marketing licence for its LHRH agonist Leuprogel (leuprolide acetate for subcutaneous depot injection). Currently under investigation for the treatment of advanced prostatic cancer, it is being developed in 1, 3 and 4 month sustained release dosage formulations.